No profile data available.
Drugs Made In America Acquisition Corp. (DMAA) is a financial services company in the acquisition vehicle corporations industry, based in New York, United States.
It reported revenue of $0 for fiscal year 2025, and net income of $5.94 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $263.40 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp.
Drugs Made In America Acquisition reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$263.40 million as of October 9, 2026.
Listed companies of a similar size in the same industry (acquisition vehicle corporations) include Pyrophyte Acquisition Corp. II (PAII-UN), Cantor Equity Partners I, Inc. (CEPO), Oaktree Acquisition Corp. III Life Sciences (OACC), Newbury Street II Acquisition Corp (NTWO).